查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1655329

全球液态切片市场

Liquid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计 2030 年全球液态切片市场规模将达 171 亿美元

2024 年全球液态切片市场规模估计为 63 亿美元，预计到 2030 年将达到 171 亿美元，2024-2030 年分析期间的复合年增长率为 17.9%。液态切片检测试剂套件是该报告分析的细分市场之一，预计其复合年增长率为 18.0%，到分析期结束时将达到 128 亿美元。在分析期内，液态切片仪器部分预计以 16.6% 的复合年增长率成长。

美国市场预计将达到 18 亿美元，中国市场年复合成长率将达到 17.2%

预计2024年美国液态切片市场规模将达18亿美元。中国是世界第二大经济体，预计到 2030 年市场规模将达到 26 亿美元，2024-2030 年分析期间的复合年增长率为 17.2%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 15.6% 和 15.3%。在欧洲，预计德国的复合年增长率约为 13.1%。

全球液态切片市场-主要趋势和驱动因素摘要

为什么液态切片可以彻底改变癌症的诊断和治疗？

液态切片透过提供一种非侵入性、准确​​且即时的癌症检测和监测方法，彻底改变了癌症的诊断和治疗。与需要透过手术获取样本的传统组织切片检查不同，液态切片透过分析血液样本来检测循环性肿瘤细胞(CTC)、无细胞 DNA (cfDNA) 或与癌症相关的其他生物标记。这种方法可以早期发现癌症、监测病情进展并评估治疗效果，同时最大程度地减少患者的不适。液态切片能够全面了解肿瘤的基因组成，从而彻底改变了个人化医疗，使肿瘤医生能够更有效地根据每位患者的需求制定治疗方案。随着对微创、更准确的诊断工具的需求不断增加，液态切片正迅速被接受为肿瘤学中有价值的工具。

科技进步如何推动液态切片市场的发展？

技术进步在推动液态切片的发展和应用方面发挥关键作用，液态切片更加准确、易于获取和资讯丰富。次世代定序仪(NGS) 和数位 PCR（聚合酵素链锁反应）技术的创新提高了液态切片的敏感性和特异性，使得检测血液中微量的癌症相关生物标记成为可能。这些进步使得我们能够识别更广泛的基因变异，从而更深入地了解肿瘤生物学和治疗反应。此外，先进的生物资讯工具的发展正在改善液态切片资料的分析和解释，从而有助于做出更准确和个人化的治疗决策。液态切片检测方法的不断改进正在开闢肿瘤学以外的新潜在应用，包括监测器官移植排斥、检测感染疾病和评估产前遗传状况。这些技术创新使液态切片成为精准医疗中更强大、用途更广泛的工具。

哪些市场趋势正在影响液态切片的需求？

几个关键的市场趋势正在影响液态切片的需求。这些包括更加重视个人化医疗、越来越多地采用非侵入性诊断工具以及扩大肿瘤学以外的液态切片应用。随着个人化医疗的不断受到关注，对能够提供详细基因资讯以指南标靶治疗的诊断工具的需求日益增长。液态切片是这种方法中的宝贵资产，因为它们可以提供对肿瘤遗传学的即时洞察。非侵入性诊断的趋势也推动了液态切片的需求。患者和医疗保健提供者正在寻找比传统组织切片检查侵入性更小、更舒适的替代方法。此外，液态切片还可应用于其他医疗领域，如移植监测和感染疾病检测，从而扩大市场机会。液态切片在临床试验和药物开发中的应用越来越广泛，这进一步促进了其发展，因为它为即时监测治疗反应和疾病进展提供了有价值的工具。

推动液态切片市场成长的因素是什么？

液态切片市场的成长受到多种因素的推动。液态切片为患者提供了一种比传统切片检查更友善的替代方法，其主要推动力是全球癌症发病率的上升和对微创诊断方法的需求的增加。基因组和分子诊断技术的进步提高了液态切片的准确性和效用，使其成为对临床医生和患者更具吸引力的选择。个人化医疗的日益采用以及对癌症进展和治疗结果的即时监测的需求也促进了市场的扩张。此外，扩大肿瘤学以外的应用，如移植监测和产前检测，也正在创造新的成长机会。液态切片临床试验和研发的增加进一步推动了市场的发展，这继续检验和扩大了这项创新技术的潜在应用。

部分

提供（检测试剂套件、仪器、服务）；技术（多基因平行分析、单基因分析）；应用（癌症、非癌症）；最终用途（参考实验室、医院/医生实验室、学术/研究中心、其他最终用途）

调查企业范例（共42家企业）

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP13050

Global Liquid Biopsy Market to Reach US$17.1 Billion by 2030

The global market for Liquid Biopsy estimated at US$6.3 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. Liquid Biopsy Assay Kits, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$12.8 Billion by the end of the analysis period. Growth in the Liquid Biopsy Instruments segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 17.2% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR.

Global Liquid Biopsy Market - Key Trends & Drivers Summarized

Why Is Liquid Biopsy Revolutionizing Cancer Diagnosis and Treatment?

Liquid biopsy is revolutionizing the field of cancer diagnosis and treatment by offering a non-invasive, accurate, and real-time method to detect and monitor cancer. Unlike traditional tissue biopsies, which require surgical procedures to obtain samples, liquid biopsies involve analyzing a blood sample to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers associated with cancer. This approach allows for the early detection of cancer, monitoring of disease progression, and assessment of treatment efficacy, all with minimal discomfort to the patient. The ability of liquid biopsies to provide comprehensive insights into the genetic makeup of tumors is transforming personalized medicine, enabling oncologists to tailor treatments to individual patients' needs more effectively. As the demand for less invasive, more accurate diagnostic tools grows, liquid biopsy is rapidly gaining acceptance as a valuable tool in oncology.

How Are Technological Advancements Driving the Liquid Biopsy Market?

Technological advancements are playing a crucial role in driving the growth and adoption of liquid biopsy, making it more accurate, accessible, and informative. Innovations in next-generation sequencing (NGS) and digital PCR (Polymerase Chain Reaction) technologies are enhancing the sensitivity and specificity of liquid biopsies, allowing for the detection of minute amounts of cancer-related biomarkers in the blood. These advancements are enabling the identification of a broader range of genetic mutations, providing deeper insights into tumor biology and treatment response. Additionally, the development of advanced bioinformatics tools is improving the analysis and interpretation of liquid biopsy data, facilitating more precise and personalized treatment decisions. The ongoing refinement of liquid biopsy assays is also expanding their application beyond oncology, with potential uses in monitoring organ transplant rejection, detecting infectious diseases, and assessing prenatal genetic conditions. These technological innovations are making liquid biopsy a more powerful and versatile tool in precision medicine.

What Market Trends Are Shaping the Demand for Liquid Biopsy?

Several key market trends are shaping the demand for liquid biopsy, including the increasing emphasis on personalized medicine, the growing adoption of non-invasive diagnostic tools, and the expansion of liquid biopsy applications beyond oncology. As personalized medicine continues to gain traction, there is a growing need for diagnostic tools that can provide detailed genetic information to guide targeted therapies. Liquid biopsy's ability to offer real-time insights into tumor genetics makes it a valuable asset in this approach. The trend towards non-invasive diagnostics is also driving demand for liquid biopsy, as patients and healthcare providers seek less invasive, more comfortable alternatives to traditional tissue biopsies. Additionally, the potential for liquid biopsy to be used in other areas of medicine, such as transplant monitoring and infectious disease detection, is expanding its market opportunities. The increasing use of liquid biopsy in clinical trials and drug development is further contributing to its growth, as it provides a valuable tool for monitoring treatment response and disease progression in real-time.

What Is Driving the Growth in the Liquid Biopsy Market?

The growth in the liquid biopsy market is driven by several factors. The rising incidence of cancer worldwide and the growing demand for less invasive diagnostic methods are major drivers, as liquid biopsy offers a more patient-friendly alternative to traditional biopsies. Technological advancements in genomics and molecular diagnostics are enhancing the accuracy and utility of liquid biopsy, making it a more attractive option for both clinicians and patients. The increasing adoption of personalized medicine and the need for real-time monitoring of cancer progression and treatment response are also contributing to the market's expansion. Additionally, the broadening of liquid biopsy applications beyond oncology, such as in transplant monitoring and prenatal testing, is creating new opportunities for growth. The growing number of clinical trials and research studies utilizing liquid biopsy is further supporting market development, as these efforts continue to validate and expand the potential uses of this innovative technology.

SCOPE OF STUDY:

The report analyzes the Liquid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assay Kits, Instruments, Services); Technology (Multi Gene Parallel Analysis, Single Gene Analysis); Application (Cancer, Non-Cancer); End-Use (Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Liquid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Clinical Applications Propel Growth in the Liquid Biopsy Market
    • Advancements in Circulating Tumor DNA (ctDNA) Technologies Drive Diagnostic Innovations
    • Integration of Liquid Biopsy with Precision Oncology Enhances Treatment Personalization
    • Rising Prevalence of Cancer Worldwide Boosts Demand for Non-Invasive Diagnostic Methods
    • Technological Breakthroughs in Single-Cell Analysis Expand Capabilities of Liquid Biopsy
    • FDA Approvals Accelerate Adoption of Liquid Biopsy Tests in Clinical Settings
    • Collaborations between Biotech Firms and Academic Institutions Fuel Research and Development
    • Growing Investment in Personalized Medicine Spurs Development of Targeted Therapies Using Liquid Biopsy
    • Market Challenges Posed by Sensitivity and Specificity Concerns in Early Cancer Detection
    • Impact of Artificial Intelligence on Enhancing Accuracy and Speed of Liquid Biopsy Analysis
    • Insurance Coverage and Reimbursement Policies Shape the Liquid Biopsy Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Multi Gene Parallel Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Multi Gene Parallel Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Single Gene Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Non-Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Non-Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Academic & Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Liquid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION